Clinical trial
Octreotide in Preventing or Reducing Diarrhea in Patients Receiving…
NCT00075868 · Radiation Therapy Oncology Group, Other · Completed
Key facts
| NCT number | NCT00075868 |
|---|---|
| Title | Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer |
| Official title | A Randomized, Double Blind, Placebo-Controlled Phase III Study To Determine The Efficacy Of Sandostatin LAR® Depot (Octreotide Acetate) In Preventing Or Reducing The Severity Of Chemoradiation-Induced Diarrhea In Patients With Anal Or Rectal Cancer |
| Lead sponsor | Radiation Therapy Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Anal Cancer, Colorectal Cancer, Drug/Agent Toxicity by Tissue/Organ, Radiation Enteritis |
| Intervention type | Drug, Other |
| Interventions | octreotide acetate, Placebo |
| Enrollment | 233 |
| Start date | Dec 1, 2003 |
| Primary completion | Aug 1, 2006 |
| First posted | Jan 13, 2004 |
| Last update posted | Nov 17, 2015 |
| Countries | United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: